Health committee  Thank you, Mr. Chair and members of the committee. Bonjour. My name is Cole Pinnow, and I'm the president of Pfizer Canada. It has been one year since this pandemic was declared. Since then, Pfizer-BioNTech successfully developed a safe and efficacious vaccine for the preven

Health committee  All the research to date on our vaccine has been done with two doses that have a schedule of 21 days. The recommendation that's been put in place by NACI, as highlighted earlier, in Canada is the only one in the world that is recommending an extended dose delivery.

Health committee  The data that we've seen from a real-world evidence perspective that has been used to make arguments to extend the dose schedule has been with regard to much younger populations. The fact is that we don't have any data after two months to know what the impact of one dose will be.

Health committee  All of the research that we're doing today on variants—and again I'm happy to go into detail, if you'd like, on that subject—is with patients who have received two doses 21 days apart.

Health committee  I'm not aware if it has.

Health committee  Not as far as I'm aware.

Health committee  I really believe that it's in Canadians' best interests to support whatever national program for vaccination has been determined by the government, but I do agree that differences between different health agencies—and I point to the product monograph that has been agreed to with

Health committee  We understand that it is other health professionals' authority to determine what the dose schedule is.

Health committee  I can't comment any further on that.

Health committee  We have provided a status update on the development program that we're working on, so we have had conversations about that, but we have not formally begun discussions on boosters as of yet.

Health committee  Canada is on par with the rest of the world in discussing the status of both boosters and variants as we continue to evaluate the situation that could be emerging in the future.

Health committee  We are now completing a study on adolescents between the ages of 12 and 16. We anticipate having that data filed here in a couple of months. We will then initiate a program for children aged 5 to 11. We are also currently conducting clinical studies, including here in Canada, for

Health committee  Mr. Chair, I'll respond to the first question, and then ask the member to clarify the second question. As I stated in my opening remarks, when we first identified the opportunity to bring a vaccine to market, we did work collaboratively with the Canadian government. We issued a

Health committee  We went from 1.3 billion doses on a global basis to 2 billion doses in the months of January and February, concurrent to us making changes to the Belgium facility.

Health committee  Just to be clear, it wasn't important to get a deal in place. We had our agreement in place before Health Canada authorized the rolling submission forecast, but it was critical to accelerating and allowing us to bring vaccines to Canada in December.